DrugId:  1
1. Name:  SC12267
2. Groups:  Investigational
3. Description:  SC12267 is a novel, small molecule agent from the class of DMARDs (disease modifying anti-rheumatic drug) for the therapy of autoimmune diseases such as rheumatoid arthritis or multiple sclerosis. Through highly selective inhibition of pyrimidine biosynthesis, it controls the growth of rapidly proliferating cells, especially of lymphocytes, which are important for the immune response.
4. Indication:  Investigated for use/treatment in multiple sclerosis and rheumatoid arthritis.
DrugId:  2
1. Name:  PMI-001
2. Groups:  Investigational
3. Description:  PMI-001 is a stand-alone, disease-modifying, anti-rheumatic drug (DMARD) being developed by Phytomedics Inc. It is an extract of the roots of an undisclosed perennial shrub which interferes with the production of IL-2 and COX-2 proteins, for the potential treatment of autoimmune diseases, such as rheumatoid arthritis, lupus erythematosus and psoriasis.
4. Indication:  Investigated for use/treatment in rheumatoid arthritis.
DrugId:  3
1. Name:  Benzathine benzylpenicillin
2. Groups:  Approved, Vet approved
3. Description:  Benzathine benzylpenicillin is a form of penicillin also known as benzathine penicillin. It is an B-lactam antibiotic useful for the treatment of a number of bacterial infections. These include This includes; syphilis, necrotizing enterocolitis, diphtheria, gas gangrene, leptospirosis, cellulitis, pneumonia, strep throat and tetanus.Side effects include diarrhea, seizures, and allergic reactions including anaphylaxis. Benzathine benzylpenicllin is considered long acting B-lactam antibiotic.
4. Indication:  For the treatment of several infections include: acute glomerulonephritis, respiratory tract infections, rheumatic fever and chorea, rheumatic heart disease, rheumatic heart disease, syphilis and other venereal diseases.
DrugId:  4
1. Name:  Tocilizumab
2. Groups:  Approved
3. Description:  Tocilizumab is a recombinant, humanized, anti-human interleukin 6 (IL-6) receptor monoclonal antibody that achieves a significant therapeutic response rate. The light chain is made up of 214 amino acids. The heavy chain is made up of 448 amino acids. The four polypeptide chains are linked intra- and inter-molecularly by disulfide bonds. FDA approved on January 8, 2010. Tocilizumab (injection) was further approved by the FDA for the treatment of adults with giant cell arteritis, an inflammation of the blood vessels (vasculitis) in May, 2017. In a double-blind, placebo-controlled study, the patients achieved sustained remission from Week 12 through Week 52, which was associated with significant improvements in symptoms of giant cell arteritis, normalization of inflammatory laboratory tests and tapering the use of corticosteroids [2].
4. Indication:  Indicated for the treatment of adult patients with moderately to severely active rheumatoid arthritis (RA) who have had an inadequate response to one or more Disease-Modifying Anti-Rheumatic Drugs (DMARDs). It is also indicated for the treatment of active polyarticular juvenile idiopathic arthritis (PJIA) and active systemic juvenile idiopathic arthritis (SJIA) in patients 2 years of age and older.
DrugId:  5
1. Name:  Lornoxicam
2. Groups:  Approved, Investigational
3. Description:  Lornoxicam (chlortenoxicam) is a new nonsteroidal anti-inflammatory drug (NSAID) of the oxicam class with analgesic, anti-inflammatory and antipyretic properties. Lornoxicam differs from other oxicam compounds in its potent inhibition of prostaglandin biosynthesis, a property that explains the particularly pronounced efficacy of the drug. Lornoxicam is approved for use in Japan.
4. Indication:  For the treatment of acute mild to moderate pain, as well as pain and inflammation of the joints caused by certain types of rheumatic diseases.
DrugId:  6
1. Name:  Interleukin-10
2. Groups:  Investigational
3. Description:  Interleukin-10 has been used in trials studying the prevention and treatment of Vasculitis, Pancreatitis, Bile Duct Diseases, Pancreatic Diseases, and Gallbladder Diseases, among others.
4. Indication:  Not Available
DrugId:  7
1. Name:  Betamethasone
2. Groups:  Approved, Vet approved
3. Description:  A glucocorticoid given orally, parenterally, by local injection, by inhalation, or applied topically in the management of various disorders in which corticosteroids are indicated. Its lack of mineralocorticoid properties makes betamethasone particularly suitable for treating cerebral edema and congenital adrenal hyperplasia. (From Martindale, The Extra Pharmacopoeia, 30th ed, p724)
4. Indication:  Topical use (cream, lotion and ointment): for relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses.Topical use (foam): relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses of the scalp.Systemic use: for the treatment of edocrine disorders, rheumatic disorders, collagen diseases, dermatological diseases, allergic states, ophthalmic diseases, respiratory diseases, hematologic disorders, neoplastic diseases, edematous states, gastrointestinal diseases, tuberculous meningitis and trichinosis.
DrugId:  8
1. Name:  Dexamethasone
2. Groups:  Approved, Investigational, Vet approved
3. Description:  An anti-inflammatory 9-fluoro-glucocorticoid. [PubChem]
4. Indication:  Injection: for the treatment of endocrine disorders, rheumatic D=disorders, collagen diseases, dermatologic diseases, allergic statesc, ophthalmic diseases, gastrointestinal diseases, respiratory diseases, hematologic disorders, neoplastic diseases, edematous states, cerebral edema.Ophthalmic ointment and solution: for the treatment of steroid responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe.Ophthalmic solution only: for the treatment of steroid responsive inflammatory conditions of the external auditory meatusTopic cream: for relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatosesOral aerosol: for the treatment of bronchial asthma and related corticosteroid responsive bronchospastic states intractable to adequate trial of conventional therapyIntranasal aerosol: for the treatment of allergic ot inflammatory nasal conditions, and nasal polyps
DrugId:  9
1. Name:  NVS antibody
2. Groups:  Investigational
3. Description:  This drug has been developed using Medarex's UltiMAb Human Antibody Development System to treat autoimmune diseases.
4. Indication:  Investigated for use/treatment in autoimmune diseases and rheumatoid arthritis.
DrugId:  10
1. Name:  Burlulipase
2. Groups:  Investigational
3. Description:  Burlulipase has been used in trials studying the treatment of Lung Diseases, Cystic Fibrosis, Pancreatic Insufficiency, Digestive System Diseases, and Respiratory Tract Diseases.
4. Indication:  Not Available
DrugId:  11
1. Name:  TRX1
2. Groups:  Investigational
3. Description:  TRX1 is a humanized antibody that binds to the CD4 receptor found on a subset of T cells. TRX1 is being developed for the potential treatment of autoimmune diseases in collaboration with Genentech, Inc. TolerRx is currently conducting a Phase I clinical study of TRX1 in the United Kingdom.
4. Indication:  Investigated for use/treatment in autoimmune diseases.
DrugId:  12
1. Name:  PN0621
2. Groups:  Investigational
3. Description:  PN0621 is an anti-TNF, domain antibody (dAb) based therapeutic. It targets tumour necrosis factor (TNF) to treat auto-immune inflammatory diseases such as rheumatoid arthritis. It is being developed by Peptech.
4. Indication:  Intended for the treatment of auto-immune diseases such as rheumatoid arthritis, psoriasis and Crohn's disease.
DrugId:  13
1. Name:  Lexaptepid Pegol
2. Groups:  Investigational
3. Description:  Lexaptepid Pegol has been used in trials studying the treatment of Anemia, Inflammation, Chronic Diseases, End Stage Renal Disease, and Anemia of Chronic Disease.
4. Indication:  Not Available
DrugId:  14
1. Name:  R1295
2. Groups:  Investigational
3. Description:  R1295 is an integrin antagonist currently in clinical trials for the treatment of rheumatoid arthritis. Integrins are associated to the pathology seen in some of the autoimmune diseases such as rheumatoid arthritis. 
4. Indication:  Investigated for use/treatment in rheumatoid arthritis.
DrugId:  15
1. Name:  Polihexanide
2. Groups:  Approved, Investigational
3. Description:  Polihexanide has been used in trials studying the treatment, prevention, and supportive care of Caries, Neoplasm, Skin Diseases, Nail Diseases, and Dental Plaque, among others.
4. Indication:  Not Available
DrugId:  16
1. Name:  LX-2931
2. Groups:  Investigational
3. Description:  Not Available
4. Indication:  Investigated for use/treatment in rheumatoid arthritis, inflammatory disorders (unspecified), and autoimmune diseases.
DrugId:  17
1. Name:  humanized SMART Anti-IL-12 Antibody
2. Groups:  Investigational
3. Description:  The humanized anti-IL-12 antibody is an important addition to PDL's already strong pipeline of humanized antibodies being developed for the treatment of autoimmune diseases. SMART Anti-IL-12 Antibody was humanized at PDL from a murine anti-IL-12 antibody that was licensed, together with certain intellectual property related to anti-IL-12 therapy, from Hoffmann-La Roche Inc. IL-12 is a cytokine that may have considerable potential as a target in the therapy of autoimmune diseases.
4. Indication:  Investigated for use/treatment in autoimmune diseases and inflammatory disorders (unspecified).
DrugId:  18
1. Name:  KB002
2. Groups:  Investigational
3. Description:  KB002 is an engineered human IgG1k antibody engineered human. It is developed for the treatment of autoimmune diseases, initially rheumatoid arthritis.
4. Indication:  Investigated for use/treatment in rheumatoid arthritis.
DrugId:  19
1. Name:  PDE4
2. Groups:  Investigational
3. Description:  Merck has developed a selective PDE4 inhibitor for the treatment of inflammatory diseases, such as asthma and chronic obstructive pulmonary disease. Whereas the potential therapeutic utility of PDE4 inhibition has been demonstrated in various preclinical animal models (e.g., in rheumatoid arthritis and multiple sclerosis), clinical evaluation has been restricted by dose-limiting side effects, mainly nausea and emesis.
4. Indication:  Investigated for use/treatment in asthma and chronic obstructive pulmonary disease (COPD).
DrugId:  20
1. Name:  INCB3284
2. Groups:  Investigational
3. Description:  INCB3284 is a CCR2 antagonist for Inflammation-driven Diseases.
4. Indication:  Investigated for use/treatment in inflammatory disorders (unspecified).
DrugId:  21
1. Name:  NCX 950
2. Groups:  Investigational
3. Description:  NCX 950, beta2-adrenoceptor agonists is widely used in the treatment of pulmonary diseases.
4. Indication:  Investigated for use/treatment in asthma and chronic obstructive pulmonary disease (COPD).
DrugId:  22
1. Name:  Inosine 5'-sulfate
2. Groups:  Investigational
3. Description:  Not Available
4. Indication:  Investigated for use/treatment in gastrointestinal diseases and disorders (miscellaneous), inflammatory bowel disease, and ulcerative colitis.
DrugId:  23
1. Name:  AVI-4020
2. Groups:  Investigational
3. Description:  AVI-4020 is a neugene antisense drug candidate for the treatment of patients with acute West Nile virus disease who have serious neurological impairment (WNV neuroinvasive disease).
4. Indication:  Investigated for use/treatment in infectious and parasitic disease (unspecified) and viral infection.
DrugId:  24
1. Name:  Namilumab
2. Groups:  Investigational
3. Description:  Namilumab has been used in trials studying the treatment of Plaque Psoriasis and Rheumatoid Arthritis.
4. Indication:  Not Available
DrugId:  25
1. Name:  MIV-701
2. Groups:  Investigational
3. Description:  MIV-701 is a selective, potent inhibitor of the protease Cathepsin K. It is developed for the treatment of osteoporosis.
4. Indication:  Investigated for use/treatment in osteoporosis.
